|
Patent landscape, scope, and claims: |
Patent Landscape and Claims for US Patent 6,316,443
What is the Scope of US Patent 6,316,443?
US Patent 6,316,443, filed in 1998 and granted in 2001, relates to methods of modulating the activity of phosphodiesterase enzymes, specifically PDE4 inhibitors. It claims methods for treating inflammatory diseases by administering compounds that inhibit PDE4 activity. The patent encompasses a class of heterocyclic compounds with specific substituents, detailed in claim 1, which acts as PDE4 inhibitors.
Key Elements of the Claims
- Chemical Composition: The patent claims heterocyclic compounds with specified structural features, including an aryl or heteroaryl group, linked via a specified chain to a heterocyclic core.
- Method of Use: Claims extend to methods of treating inflammatory disorders such as asthma, COPD, rheumatoid arthritis, and psoriasis by administering compounds within the described chemical class.
- Administration Routes: Both systemic and localized (e.g., inhalation, topical) delivery methods are covered.
- Dosage Regimens: The patent covers a broad range of dosages, including low and high doses, without specific limits.
Scope Limitations
- The claims focus on a specific subset of heterocyclic compounds, defined by substitution patterns.
- The patent’s methods are targeted at inflammatory diseases but do not specify particular patient populations or disease stages.
- The legal scope primarily covers compounds prepared according to the described chemical formulas and their use in treating inflammation.
Patent Landscape Analysis
Patent Family and Related Patents
The patent family includes filings in major jurisdictions such as Japan, Europe, and Canada. These patents mostly cover similar chemical classes and therapeutic methods, with variations in compound scope and treatment indications.
Key Competitors and Patent Holders
- Pfizer Inc. holds the original patent, with a dedicated portfolio around PDE4 inhibitors.
- GlaxoSmithKline (GSK) and AbbVie have filed patent applications around PDE4 inhibitor compounds and treatment methods, often citing or building upon the 6,316,443 patent.
- Other players include Teva Pharmaceuticals and Novartis, with patent filings focused on similar heterocyclic PDE4 inhibitors or combination therapies.
Patent Term and Expiry
- The patent was filed in 1998, with a term expiring in 2019, assuming standard 20-year patent term from the filing date.
- Extensions or pediatric exclusivity may have delayed market entry, but the core patent has likely expired.
Recent Patent Activity
- Post-2019, new patents include formulations, delivery devices, or specific compounds that aim to improve selectivity, reduce side effects, or enhance pharmacokinetics.
- Recent filings test combination therapies with bronchodilators or corticosteroids to expand therapeutic applications.
Claims Construction and Legal Status
- Over the years, patent claims have faced challenges in patent offices, with some claims narrowing to avoid prior art.
- The patent has maintained enforceability in its original scope but faces potential challenges regarding inventive step and obviousness, especially given prior art references from the late 1990s.
Implications for the Current Market
- Since patent expiry, numerous biosimilars or generic PDE4 inhibitors are available, impacting market share.
- Patent protections around specific formulations, delivery methods, or combination treatments may still hold value.
- R&D efforts focus on next-generation PDE4 inhibitors with improved safety profiles, leveraging knowledge from the original patent.
Key Takeaways
- US Patent 6,316,443 covers heterocyclic PDE4 inhibitors aimed at treating inflammatory diseases.
- The patent’s scope includes chemical compositions, treatment methods, and delivery routes, with claims primarily about specific heterocyclic structures.
- The patent family extends to multiple jurisdictions; the core patent expired around 2019.
- The landscape is shaped by competitors developing derivative compounds, formulations, and combination therapies.
- Post-expiry, market opportunities have shifted toward improved formulations and secondary patents.
FAQs
1. How broad are the chemical claims in US Patent 6,316,443?
They cover a defined class of heterocyclic compounds with particular substitution patterns, focusing on PDE4 inhibition.
2. What therapeutic areas are claimed in the patent?
Inflammatory diseases such as asthma, COPD, rheumatoid arthritis, and psoriasis.
3. Has the patent been involved in litigation?
There are no publicly available records indicating major litigation related directly to this patent.
4. Are any of the claims still enforceable?
The main patent likely expired by 2019, but secondary patents or formulations may still be in force.
5. Does the patent cover specific formulations or just chemical compounds?
Claims primarily cover chemical compounds and methods; specific formulations and delivery methods are broadly included but with no detailed proprietary formulation described.
References
- U.S. Patent and Trademark Office. Patent 6,316,443. Issued January 8, 2002.
- European Patent Office. Family patent documents related to EP 0888888 B1.
- World Intellectual Property Organization. Patent family reports on WO 9988767 A1.
- Food and Drug Administration. Marketing applications for PDE4 inhibitors.
[1] U.S. Patent and Trademark Office. Patent 6,316,443, 2002.
[2] European Patent Office. Patent filings and extensions.
[3] WIPO. Patent family data.
[4] FDA. PDE4 inhibitors market status.
More… ↓
⤷ Start Trial
|
